BDTX — Black Diamond Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $272.04m
- $140.64m
Annual cashflow statement for Black Diamond Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -35.3 | -67.3 | -126 | -91.2 | -82.4 |
| Depreciation | |||||
| Non-Cash Items | 10.1 | 10 | 18.2 | 15.5 | 11.6 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.463 | 5.04 | 7.02 | -9.9 | 3.69 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -24.7 | -52.1 | -100 | -85.1 | -66.7 |
| Capital Expenditures | -0.021 | -0.142 | -2.71 | -0.192 | -0.033 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -282 | 133 | 53.6 | 16.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.021 | -282 | 131 | 53.4 | 16.3 |
| Financing Cash Flow Items | -1.74 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 128 | 215 | 0.729 | 0.177 | 71.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 103 | -119 | 31.2 | -31.5 | 21.6 |